RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
安罗替尼在中国转移性乳腺癌患者中的疗效：一项回顾性观察性研究
英文原题：Efficacy of anlotinib in Chinese patients with metastatic breast cancer: A retrospective observational study.
查看英文原题
Efficacy of anlotinib in Chinese patients with metastatic breast cancer: A retrospective observational study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
安罗替尼是一种多靶点酪氨酸激酶抑制剂，可抑制肿瘤血管生成、增殖和转移，促进血管正常化，增强T细胞和NK细胞活性及浸润，并重塑肿瘤微环境、协同增强免疫。
本研究旨在评估安罗替尼用于多线治疗后晚期转移性乳腺癌（MBC）的疗效。纳入2019年1月1日至2023年6月30日在郑州大学附属肿瘤医院接受安罗替尼治疗的晚期MBC患者，并分析客观缓解率、无进展生存期及不良反应。
结果显示，客观缓解率（ORR）为23.6%，疾病控制率（DCR）为69.1%。单药治疗和联合治疗的DCR分别为66.7%和69.6%；其中联合化疗效果最佳（79.3%），联合免疫治疗次之。既往接受抗血管生成治疗的MBC患者DCR更高，为88.9%。Kaplan-Meier生存分析显示，HER2阳性MBC患者中位无进展生存期（mPFS）为4.17个月（95%置信区间[CI]，1.758–6.582个月），HER2阴性患者为7.83个月（95% CI，2.416–9.104个月）。激素受体阳性MBC患者mPFS为5.76个月（95% CI，3.231–8.298个月），三阴性乳腺癌患者为7.83个月（95% CI，3.182–12.478个月）。常见不良反应包括乏力（20.0%）、高血压（21.8%）和肝功能异常（18.2%），其次为骨髓抑制（16.4%）、食欲减退（14.5%）、甲状腺功能减退（14.5%）和腹泻（14.5%）。
总体而言，安罗替尼单药或联合治疗可作为转移性乳腺癌三线及以上治疗的可行策略，其不良反应总体可耐受且可控制。
展开英文摘要原文
Anlotinib, a multitarget tyrosine kinase inhibitor, can inhibit tumour angiogenesis proliferation, metastasis, promote vascular normalization, increase T cell and NK cell activity and infiltration, remodel tumour microenvironment and synergistic immune enhancement.
Our study aimes to evaluate the efficacy of anlotinib in the treatment of advanced metastatic breast cancer (MBC) after multiple lines of therapy. Patients included were treated with anlotinib for advanced MBC in the Affiliated Cancer Hospital of Zhengzhou University from 1 January 2019 to 30 June 2023. The objective remission rate, disease-free progression survival and adverse reactions were analysed.
We compared and analysed the efficacy of anlotinib in the treatment of advanced metastatic breast cancer, which showed that ORR was 23. 6% and DCR was 69. 1%. The DCR of monotherapy was 66. 7% and that of combination therapy was 69. 6% in MBC patients. The combination therapy, combined with chemotherapy had the best effect (79. 3%), combined with immunotherapy came second.
In addition, the DCR (88. 9%) was higher in MBC patients having received prior antiangiogenic therapy. According to the Kaplan-Meier (K-M) survival estimate analysis, the mPFS was 4. 17 months (95% CI, 1. 758-6. 582 months) in Her-2 positive MBC patients, and 7. 83 months (95% CI, 2. 416-9. 104) in Her-2 negative MBC patients. The mPFS was 5. 76 months (95% CI, 3. 231-8. 298 m) in HR positive MBC patients, 7. 83 months (95% CI, 3. 182-12. 478 m) in TNBC patients.
Fatigue (20. 0%), hypertension (21. 8%) and liver dysfunction (18. 2%) were common adverse reactions, followed by bone marrow suppression (16. 4%), anorexia (14. 5%), hypothyroidism (14. 5%) and diarrhoea (14. 5%). Altogether, Anlotinib monotherapy or combination therapy provides a viable third (or above)-line therapeutic strategy in patients with metastatic breast cancer. The adverse reactions of anlotinib are well tolerated and controllable.
论文信息
- 作者
- Liu S、Zhi W、Zhang L
- 第一作者单位
- Department of Breast disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan Province, China.China
- 通讯作者单位
- Department of Combine Traditional Chinese & Western, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan Province, China.China
- 文献类型
- 观察性研究 · 非美国政府资助研究
- 期刊
- Journal of cellular and molecular medicine2024 Mar
- 原文标识
- PubMed 37891706 · DOI 10.1111/jcmm.18008
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →